Cargando…

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer

BACKGROUND: Oestrogen receptor-negative (ER−) breast cancer is intrinsically sensitive to chemotherapy. However, tumour response is often incomplete, and relapse occurs with high frequency. The aim of this work was to analyse the molecular characteristics of residual tumours and early response to ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Legrier, Marie-Emmanuelle, Bièche, Ivan, Gaston, Julie, Beurdeley, Arnaud, Yvonnet, Vanessa, Déas, Olivier, Thuleau, Aurélie, Château-Joubert, Sophie, Servely, Jean-Luc, Vacher, Sophie, Lassalle, Myriam, Depil, Stéphane, C Tucker, Gordon, Fontaine, Jean-Jacques, Poupon, Marie-France, Roman-Roman, Sergio, Judde, Jean-Gabriel, Decaudin, Didier, Cairo, Stefano, Marangoni, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815803/
https://www.ncbi.nlm.nih.gov/pubmed/26695443
http://dx.doi.org/10.1038/bjc.2015.398
_version_ 1782424631975608320
author Legrier, Marie-Emmanuelle
Bièche, Ivan
Gaston, Julie
Beurdeley, Arnaud
Yvonnet, Vanessa
Déas, Olivier
Thuleau, Aurélie
Château-Joubert, Sophie
Servely, Jean-Luc
Vacher, Sophie
Lassalle, Myriam
Depil, Stéphane
C Tucker, Gordon
Fontaine, Jean-Jacques
Poupon, Marie-France
Roman-Roman, Sergio
Judde, Jean-Gabriel
Decaudin, Didier
Cairo, Stefano
Marangoni, Elisabetta
author_facet Legrier, Marie-Emmanuelle
Bièche, Ivan
Gaston, Julie
Beurdeley, Arnaud
Yvonnet, Vanessa
Déas, Olivier
Thuleau, Aurélie
Château-Joubert, Sophie
Servely, Jean-Luc
Vacher, Sophie
Lassalle, Myriam
Depil, Stéphane
C Tucker, Gordon
Fontaine, Jean-Jacques
Poupon, Marie-France
Roman-Roman, Sergio
Judde, Jean-Gabriel
Decaudin, Didier
Cairo, Stefano
Marangoni, Elisabetta
author_sort Legrier, Marie-Emmanuelle
collection PubMed
description BACKGROUND: Oestrogen receptor-negative (ER−) breast cancer is intrinsically sensitive to chemotherapy. However, tumour response is often incomplete, and relapse occurs with high frequency. The aim of this work was to analyse the molecular characteristics of residual tumours and early response to chemotherapy in patient-derived xenografts (PDXs) of breast cancer. METHODS: Gene and protein expression profiles were analysed in a panel of ER− breast cancer PDXs before and after chemotherapy treatment. Tumour and stromal interferon-gamma expression was measured in xenografts lysates by human and mouse cytokine arrays, respectively. RESULTS: The analysis of residual tumour cells in chemo-responder PDX revealed a strong overexpression of IFN-inducible genes, induced early after AC treatment and associated with increased STAT1 phosphorylation, DNA-damage and apoptosis. No increase in IFN-inducible gene expression was observed in chemo-resistant PDXs upon chemotherapy. Overexpression of IFN-related genes was associated with human IFN-γ secretion by tumour cells. CONCLUSIONS: Treatment-induced activation of the IFN/STAT1 pathway in tumour cells is associated with chemotherapy response in ER− breast cancer. Further validations in prospective clinical trials will aim to evaluate the usefulness of this signature to assist therapeutic strategies in the clinical setting.
format Online
Article
Text
id pubmed-4815803
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48158032017-01-19 Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer Legrier, Marie-Emmanuelle Bièche, Ivan Gaston, Julie Beurdeley, Arnaud Yvonnet, Vanessa Déas, Olivier Thuleau, Aurélie Château-Joubert, Sophie Servely, Jean-Luc Vacher, Sophie Lassalle, Myriam Depil, Stéphane C Tucker, Gordon Fontaine, Jean-Jacques Poupon, Marie-France Roman-Roman, Sergio Judde, Jean-Gabriel Decaudin, Didier Cairo, Stefano Marangoni, Elisabetta Br J Cancer Translational Therapeutics BACKGROUND: Oestrogen receptor-negative (ER−) breast cancer is intrinsically sensitive to chemotherapy. However, tumour response is often incomplete, and relapse occurs with high frequency. The aim of this work was to analyse the molecular characteristics of residual tumours and early response to chemotherapy in patient-derived xenografts (PDXs) of breast cancer. METHODS: Gene and protein expression profiles were analysed in a panel of ER− breast cancer PDXs before and after chemotherapy treatment. Tumour and stromal interferon-gamma expression was measured in xenografts lysates by human and mouse cytokine arrays, respectively. RESULTS: The analysis of residual tumour cells in chemo-responder PDX revealed a strong overexpression of IFN-inducible genes, induced early after AC treatment and associated with increased STAT1 phosphorylation, DNA-damage and apoptosis. No increase in IFN-inducible gene expression was observed in chemo-resistant PDXs upon chemotherapy. Overexpression of IFN-related genes was associated with human IFN-γ secretion by tumour cells. CONCLUSIONS: Treatment-induced activation of the IFN/STAT1 pathway in tumour cells is associated with chemotherapy response in ER− breast cancer. Further validations in prospective clinical trials will aim to evaluate the usefulness of this signature to assist therapeutic strategies in the clinical setting. Nature Publishing Group 2016-01-19 2015-12-22 /pmc/articles/PMC4815803/ /pubmed/26695443 http://dx.doi.org/10.1038/bjc.2015.398 Text en Copyright © 2016 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Translational Therapeutics
Legrier, Marie-Emmanuelle
Bièche, Ivan
Gaston, Julie
Beurdeley, Arnaud
Yvonnet, Vanessa
Déas, Olivier
Thuleau, Aurélie
Château-Joubert, Sophie
Servely, Jean-Luc
Vacher, Sophie
Lassalle, Myriam
Depil, Stéphane
C Tucker, Gordon
Fontaine, Jean-Jacques
Poupon, Marie-France
Roman-Roman, Sergio
Judde, Jean-Gabriel
Decaudin, Didier
Cairo, Stefano
Marangoni, Elisabetta
Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
title Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
title_full Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
title_fullStr Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
title_full_unstemmed Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
title_short Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
title_sort activation of ifn/stat1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815803/
https://www.ncbi.nlm.nih.gov/pubmed/26695443
http://dx.doi.org/10.1038/bjc.2015.398
work_keys_str_mv AT legriermarieemmanuelle activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT biecheivan activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT gastonjulie activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT beurdeleyarnaud activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT yvonnetvanessa activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT deasolivier activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT thuleauaurelie activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT chateaujoubertsophie activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT servelyjeanluc activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT vachersophie activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT lassallemyriam activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT depilstephane activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT ctuckergordon activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT fontainejeanjacques activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT pouponmariefrance activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT romanromansergio activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT juddejeangabriel activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT decaudindidier activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT cairostefano activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer
AT marangonielisabetta activationofifnstat1signallingpredictsresponsetochemotherapyinoestrogenreceptornegativebreastcancer